As I'm writing this, people continue to stream onto the Boeing 757 that promises to lift me out of San Antonio and return me home. Already, I've reconnected with like-minded souls from AAD 08 — a few dermatologists and aetheticians whom I met at the meeting are also guests on my United Airlines flight back to Los Angeles. What did those folks take away from this winter's meeting?
Just as the meeting was disbanding, an organization called the Indoor Tanning Association and a handful of physicians lashed out at the AAD for charging skin care companies $10,000 a pop to "buy" the use of AAD's seal of product approval. Fox Business ran a [removed]story[/removed] on this issue. It brings up some valid questions, such as, is it ethical, period?
And now for something completely different: the AAD sessions. There were probably a hundred of these break-out sessions conducted over the weekend, and highlighs of the best of these sessions are starting to trickle out.
Celgene Corp. announced that clinical data from a completed Phase II study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis were presented for the first time at the meeting. Kim Papp, MD, PhD, Assistant Clinical Professor of Medicine at the University of Western Ontario, Canada, presented results from a randomized, 260-patient, multi-center study. Read more.
NexMed Inc. presented data on NM100060, a topical onychomycosis (nail fungus) investigative drug product, in a presentation entitled, "Terbinafine HCI Nail Solution with and without Nail Penetration Enhancer: Evaluation of Minimum Inhibitory Concentration and Minimum Fungicidal Concentrations." NM100060 is a topical application of Lamisil (terbinafine hydrochloride), formulated with terbinafine and NexMed's patented NexACT permeation enhancer, and it is being developed to treat onychomycosis. Detail abounds [removed]here[/removed].
Methotrexate is an effective treatment for children with severe atopic dermatitis, reported Christopher Rouse, MD, Senior Resident, Department of Dermatology, St. Louis University School of Medicine. He and his colleagues indicated that atopic dermatitis is the most common cause of severe skin disease in children. Research on systemic treatments is limited. "Case reports have documented the efficacy of methotrexate for the treatment of severe atopic dermatitis in adults, but no information is published on treatment in children with this disease," Dr. Rouse said in a presentation on February 3. News coverage of this story can be found here.
More information about groundbreaking research in dermatoogy and aesthetics will continue to reverberate long after AAD 08. Keep it tuned to PSP and we will report the results as they become available.
